NextCure, Inc. (NXTC): Price and Financial Metrics


NextCure, Inc. (NXTC): $4.65

-0.12 (-2.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NXTC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NXTC Stock Price Chart Interactive Chart >

Price chart for NXTC

NXTC Price/Volume Stats

Current price $4.65 52-week high $9.18
Prev. close $4.77 52-week low $3.25
Day low $4.65 Volume 300,700
Day high $4.88 Avg. volume 153,264
50-day MA $4.20 Dividend yield N/A
200-day MA $5.67 Market Cap 129.02M

NextCure, Inc. (NXTC) Company Bio


NextCure, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.


NXTC Latest News Stream


Event/Time News Detail
Loading, please wait...

NXTC Latest Social Stream


Loading social stream, please wait...

View Full NXTC Social Stream

Latest NXTC News From Around the Web

Below are the latest news stories about NextCure Inc that investors may wish to consider to help them evaluate NXTC as an investment opportunity.

Needham Maintains Their Buy Rating on NextCure (NXTC)

In a report released today, Gil Blum from Needham maintained a Buy rating on NextCure (NXTC – Research Report), with a price target of $14.00. The company's shares closed last Monday at $5.94, close to its 52-week low of $5.59. According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -28.1% and a 7.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. NextCure has an analyst consensus of Strong Buy, with a price target consensus of $20.67.

Howard Kim on TipRanks | December 13, 2021

NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

BELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data in oral and poster presentations at the American Society of Hematology (ASH) annual meeting in Atlanta, Georgia, and on a virtual platform. The data come from preclinical research studies in collaboration with Emory Unive

Yahoo | December 13, 2021

NextCure to Present at The JMP Securities Hematology and Oncology Summit

BELTSVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday December 7th at 11:40 am ET. A live audio webcast will be available through the Investors section of the company’s website

Yahoo | November 30, 2021

NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

BELTSVILLE, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30th. An audio webcast of the pre-recorded The post NextCure to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference appeared first on ForexTV .

ForexTV | November 22, 2021

NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer (SITC) annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC318, a Siglec-15 (S15) antibody, and NC410, a fusion protein of LAIR-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating NC410s impact on T cell activation and myeloid cell polarization conducted in collaboration with the National Cancer Institute at ...

Intrado Digital Media | November 13, 2021

Read More 'NXTC' Stories Here

NXTC Price Returns

1-mo 16.54%
3-mo -7.19%
6-mo -21.98%
1-year -45.17%
3-year -67.16%
5-year N/A
YTD -22.50%
2021 -44.95%
2020 -80.65%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4343 seconds.